FibroGen, Inc.

152 articles with FibroGen, Inc.

• FibroGen Provides Regulatory Update on Roxadustat

  12/18/2020

  FibroGen, Inc. announced that the U.S. Food and Drug Administration has extended the review period of the New Drug Application for roxadustat for the treatment of anemia of chronic kidney disease by three months.

• FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting

  12/2/2020

  New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndrome s (MDS) regardless of ring sideroblast (RS) or baseline e rythro poietin level Multiple analyses evaluate cardiovascular safety and efficacy of roxadustat in patients with anemia of  chronic kidney disease (CKD ) regardless of dialysis status 

• FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer

  12/1/2020

  FibroGen, Inc. (NASDAQ: FGEN) today announced the retirement of K. Peony Yu, M.D., Chief Medical Officer, and appointment of Mark Eisner, M.D., M.P.H. in that role. Dr. Yu will continue as Chief Medical Officer through December 20, 2020, the roxadustat PDUFA date, and will remain with FibroGen through March 15, 2021 serving as Executive Advisor to the CEO to support the transition. Dr. Yu joined FibroGen in 2008 and has provided key leadership

• Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease

  11/27/2020

  FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO ® (roxadustat) for the treatment of anemia of chronic kidney disease (CKD) in adult patients not on dialysis. This marks the second approval in Japan for roxadustat through the Astellas and

• FibroGen to Present at Upcoming Investor Conferences - Nov 06, 2020

  11/6/2020

  FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following healthcare conferences

• FibroGen Reports Third Quarter 2020 Financial Results

  11/5/2020

  “I am pleased with our progress with roxadustat across a number of fronts; including engagement with the FDA, commercial preparations in the U.S., and our impressive sales results in China.” said Enrique Conterno, Chief Executive Officer, FibroGen.

• 

  FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease

  10/26/2020

  FibroGen presented data from two pooled analyses from its roxadustat global Phase III development program this weekend at the American Society of Nephrology Kidney Week 2020 Reimagined conference.
• 

  Clinical Catch-Up: October 19-23

  10/26/2020

  It was another busy week for clinical trial updates and news. Here’s a look.

• FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)

  10/22/2020

  In non-dialysis and dialysis-dependent CKD patients, Major Adverse Cardiovascular Event (MACE) and MACE+ incidence rates were lowest when patients achieved hemoglobin levels ≥ 1 0 g/dL Two analyses o f pooled data from the roxadustat global Phase 3 development program t o be presented during the American Society of Nephrology Kidney Week 2020 Reimagined

• New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN Kidney Week 2020 Reimagined

  10/19/2020

  42 abstracts featuring additional insights into roxadustat and anemia of chronic kidney disease to be presented

• FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined

  10/14/2020

  Late-breaking abstracts explore cardiovascularoutcomes of patients with anemia in chronic kidney disease(CKD) treated with roxadustat, including associations with achieved hemoglobin levels and risk of Major Adverse Cardiovascular Events (MACE) and MACE+

• New Ventures Funds Rebrands as Scientia Ventures

  10/2/2020

  New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.

• FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer

  9/8/2020

  FibroGen, Inc. announced the appointment of Percy Carter, MBA, PhD, to the newly-created position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience.

• FibroGen to Present at Upcoming Investor Conferences

  9/1/2020

  FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences: Citigroup 15th Annual BioPharma Conference on September 9, 2020 at 2:25 PM Eastern Time Morgan Stanley 18 th Annual Global Healthcare Conference on September 16, 2020 at 3:30 PM Eastern Time A live audio webcast will be available on the “Events & Presentation

• FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy

  8/11/2020

  FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with non-ambulatory Duchenne muscular dystrophy (DMD). The primary objective of this global study is to evaluate the effect of pamrevlumab on muscle function in patients with DMD. Approximately 90 patients will be randomized 1:1 to rec

• FibroGen Reports Second Quarter 2020 Financial Results

  8/6/2020

  FibroGen, Inc. reported financial results for the second quarter of 2020 and provided an update on the company’s recent developments.

• FibroGen Announces New Appointments to its Board of Directors

  8/6/2020

  Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute

• FibroGen to Report Second Quarter 2020 Financial Results

  7/23/2020

  FibroGen, Inc. will announce its second quarter 2020 financial results on Thursday, August 6 after the market close.

• FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19

  6/23/2020

  FibroGen, Inc. announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with acute coronavirus 2019 infection.

• FibroGen Appoints Thane Wettig as Chief Commercial Officer

  6/22/2020

  FibroGen, Inc. announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen’s commercialization efforts, leveraging more than 30 years of global biopharmaceutical leadership and experience.